Celgene Corp (CELG) 161.74 $CELG
Final Glance: Biotechnology companies
AP - Mon Jun 09, 5:05PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
Midday Glance: Biotechnology companies
AP - Mon Jun 09, 12:19PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
Early Glance: Biotechnology companies
AP - Mon Jun 09, 9:30AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
3 Stocks That Soared Stupendously This Week
Keith Speights, The Motley Fool - Motley Fool - Sun Jun 08, 8:00AM CDT
What a week for the major indexes! The S&P 500 and Dow both ended at record highs. The success of the broader markets paled in comparison to a handful of health-care stocks, though. One of this week's soaring stocks received good news from...
Jim Cramer: No Joy in Shortville
at The Street - Fri Jun 06, 12:42PM CDT
Shorts take much more homework than longs.
Health Care Sector Equities Coverage -- Research on Neurocrine Biosciences, PDL BioPharma, Celgene, and Array BioPharma
PR Newswire - Fri Jun 06, 6:50AM CDT
On Thursday, June 05, 2014, the NASDAQ Composite ended at 4,296.23, up 1.05%, the Dow Jones Industrial Average finished the session at 16,836.11, up 0.59% and the S&P 500 closed at 1,940.46, up 0.65%. During the trading session, all of the ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day 0.16% higher at 695.40, and the index has advanced 0.32% in the previous three months. Investor-Edge has initiated coverage on the following equities: Neurocrine Biosciences Inc. (NASDAQ: NBIX), PDL BioPharma Inc. (NASDAQ: PDLI), Celgene Corp. (NASDAQ: CELG) and Array BioPharma Inc. (NASDAQ: ARRY). Free technical research on NBIX, PDLI, CELG and ARRY can be downloaded upon signing up at:
'Mad Money' Lightning Round: I'm Flying With American
at The Street - Fri Jun 06, 5:00AM CDT
Cramer is a believer in Charles Schwab and likes Gilead Sciences and Celgene.
Jim Cramer's 'Mad Money' Recap: Follow Your Own Investment Path
at The Street - Thu Jun 05, 7:08PM CDT
Investors need to be their own gurus and decide for themselves when it's time to buy and sell.
3 Reasons Why Wall Street Hates Merrimack Pharmaceuticals
George Budwell, The Motley Fool - Motley Fool - Thu Jun 05, 12:43PM CDT
A rising short interest is often times a bad omen for a stock. Specifically, the high degree of risk involved in shorting tends to ensure that short-sellers have a clear cut investing thesis for why a particular stock is overvalued. Merrimack...
Celgene to Invest $25M in New Soon-Shiong Healthcare Venture
at The Street - Thu Jun 05, 12:42PM CDT
Celgene CELG is once again partnering with billionaire drug executive Patrick Soon-Shiong. Next Tuesday, Celgene will announce a $25 million investment in NantHealth, a healthcare technology company founded Soon-Shiong, TheStreet has learned.
Watch For Today's Momo Momentum Stock: Celgene (CELG)
at The Street - Thu Jun 05, 11:52AM CDT
Trade-Ideas LLC identified Celgene (CELG) as a momo momentum candidate
Stock Market News for June 05, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Thu Jun 05, 9:06AM CDT
Benchmarks erased day’s initial losses and ended in the green after investors shrugged off dismal labor market data to focus on an encouraging services sector report
Jim Cramer's Top Stock Picks: PVH CELG REGN SKX
at The Street - Thu Jun 05, 5:00AM CDT
Cramer expects a second-half comeback for PVH while Skechers delivers solid performance.
After Yesterday's Rally of 2.13% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Wed Jun 04, 3:45PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $154.22 to a high of $159.23. Yesterday, the shares gained 2.1%, which took the trading range above the 3-day high of $155.71 on volume of 2.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Final Glance: Biotechnology companies
AP - Mon Jun 09, 5:05PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
Midday Glance: Biotechnology companies
AP - Mon Jun 09, 12:19PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
Early Glance: Biotechnology companies
AP - Mon Jun 09, 9:30AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
3 Stocks That Soared Stupendously This Week
Keith Speights, The Motley Fool - Motley Fool - Sun Jun 08, 8:00AM CDT
What a week for the major indexes! The S&P 500 and Dow both ended at record highs. The success of the broader markets paled in comparison to a handful of health-care stocks, though. One of this week's soaring stocks received good news from...
Jim Cramer: No Joy in Shortville
at The Street - Fri Jun 06, 12:42PM CDT
Shorts take much more homework than longs.
Health Care Sector Equities Coverage -- Research on Neurocrine Biosciences, PDL BioPharma, Celgene, and Array BioPharma
PR Newswire - Fri Jun 06, 6:50AM CDT
On Thursday, June 05, 2014, the NASDAQ Composite ended at 4,296.23, up 1.05%, the Dow Jones Industrial Average finished the session at 16,836.11, up 0.59% and the S&P 500 closed at 1,940.46, up 0.65%. During the trading session, all of the ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day 0.16% higher at 695.40, and the index has advanced 0.32% in the previous three months. Investor-Edge has initiated coverage on the following equities: Neurocrine Biosciences Inc. (NASDAQ: NBIX), PDL BioPharma Inc. (NASDAQ: PDLI), Celgene Corp. (NASDAQ: CELG) and Array BioPharma Inc. (NASDAQ: ARRY). Free technical research on NBIX, PDLI, CELG and ARRY can be downloaded upon signing up at:
'Mad Money' Lightning Round: I'm Flying With American
at The Street - Fri Jun 06, 5:00AM CDT
Cramer is a believer in Charles Schwab and likes Gilead Sciences and Celgene.
Jim Cramer's 'Mad Money' Recap: Follow Your Own Investment Path
at The Street - Thu Jun 05, 7:08PM CDT
Investors need to be their own gurus and decide for themselves when it's time to buy and sell.
3 Reasons Why Wall Street Hates Merrimack Pharmaceuticals
George Budwell, The Motley Fool - Motley Fool - Thu Jun 05, 12:43PM CDT
A rising short interest is often times a bad omen for a stock. Specifically, the high degree of risk involved in shorting tends to ensure that short-sellers have a clear cut investing thesis for why a particular stock is overvalued. Merrimack...
Celgene to Invest $25M in New Soon-Shiong Healthcare Venture
at The Street - Thu Jun 05, 12:42PM CDT
Celgene CELG is once again partnering with billionaire drug executive Patrick Soon-Shiong. Next Tuesday, Celgene will announce a $25 million investment in NantHealth, a healthcare technology company founded Soon-Shiong, TheStreet has learned.
Watch For Today's Momo Momentum Stock: Celgene (CELG)
at The Street - Thu Jun 05, 11:52AM CDT
Trade-Ideas LLC identified Celgene (CELG) as a momo momentum candidate
Stock Market News for June 05, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Thu Jun 05, 9:06AM CDT
Benchmarks erased day’s initial losses and ended in the green after investors shrugged off dismal labor market data to focus on an encouraging services sector report
Jim Cramer's Top Stock Picks: PVH CELG REGN SKX
at The Street - Thu Jun 05, 5:00AM CDT
Cramer expects a second-half comeback for PVH while Skechers delivers solid performance.
After Yesterday's Rally of 2.13% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Wed Jun 04, 3:45PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $154.22 to a high of $159.23. Yesterday, the shares gained 2.1%, which took the trading range above the 3-day high of $155.71 on volume of 2.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
